On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation

@article{Lesokhin2015OnBL,
  title={On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation},
  author={Alexander M Lesokhin and Margaret K. Callahan and Michael A Postow and Jedd D Wolchok},
  journal={Science Translational Medicine},
  year={2015},
  volume={7},
  pages={280sr1-280sr1}
}
The recent approvals of two drugs that block the function of the immune checkpoint programmed cell death 1 (PD-1) have firmly planted tumor immunotherapy in the mainstream of clinical oncology. We provide a historical and immunologic context for these recent advances and discuss translational studies that provide insight into the efficacy of cancer immunotherapy at the individual patient level. 
Recent Discussions
This paper has been referenced on Twitter 65 times over the past 90 days. VIEW TWEETS

From This Paper

Figures, tables, and topics from this paper.
39 Citations
102 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 39 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 102 references

A phase 1 study of PF-05082566 (anti-4-1BB) in patients with advanced cancer

  • N. Segal, A. K. Gopal, +11 authors C. Davis
  • J. Clin. Oncol
  • 2014
2 Excerpts

A randomized controlled comparison of pembrolizumab and chemotherapy in patients with ipilimumab-refractory (IPI-R) melanoma

  • A. Ribas, I. Pzanov, +18 authors O. Hamid
  • (MEL). Soc. Melanoma Res
  • 2014
1 Excerpt

Similar Papers

Loading similar papers…